These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26542454)

  • 1. Forced degradation studies of biopharmaceuticals: Selection of stress conditions.
    Tamizi E; Jouyban A
    Eur J Pharm Biopharm; 2016 Jan; 98():26-46. PubMed ID: 26542454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forced degradation of therapeutic proteins.
    Hawe A; Wiggenhorn M; van de Weert M; Garbe JH; Mahler HC; Jiskoot W
    J Pharm Sci; 2012 Mar; 101(3):895-913. PubMed ID: 22083792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical Approaches to Forced Degradation Studies of Vaccines.
    Hasija M; Aboutorabian S; Rahman N; Ausar SF
    Methods Mol Biol; 2016; 1403():853-66. PubMed ID: 27076171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of forced degradation behavior of eletriptan hydrobromide by LC and LC-MS and development of stability-indicating method.
    Jocić B; Zecević M; Zivanović L; Protić A; Jadranin M; Vajs V
    J Pharm Biomed Anal; 2009 Nov; 50(4):622-9. PubMed ID: 19250786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The application of electrochemistry to pharmaceutical stability testing--comparison with in silico prediction and chemical forced degradation approaches.
    Torres S; Brown R; Szucs R; Hawkins JM; Zelesky T; Scrivens G; Pettman A; Taylor MR
    J Pharm Biomed Anal; 2015 Nov; 115():487-501. PubMed ID: 26299525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Industry Perspective on the use of Forced Degradation Studies to Assess Comparability of Biopharmaceuticals.
    Campbell JM; Colombo S; Doyle JL; Filoti DI; Hübner G; Magnenat L; Nowinski AK; Pavon JA; Singh SM; Vo LR; Woods JM; Stokes ESE
    J Pharm Sci; 2024 Mar; 113(3):505-512. PubMed ID: 38103689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical Forced Degradation (Stress Testing) Endpoints: A Scientific Rationale and Industry Perspective.
    Zelesky T; Baertschi SW; Foti C; Allain LR; Hostyn S; Franca JR; Li Y; Marden S; Mohan S; Ultramari M; Huang Z; Adams N; Campbell JM; Jansen PJ; Kotoni D; Laue C
    J Pharm Sci; 2023 Dec; 112(12):2948-2964. PubMed ID: 37690775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: A comprehensive review.
    Sengupta P; Chatterjee B; Tekade RK
    Int J Pharm; 2018 May; 543(1-2):328-344. PubMed ID: 29635054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of design of experiments for optimization of forced degradation conditions and development of a stability-indicating method for furosemide.
    Kurmi M; Kumar S; Singh B; Singh S
    J Pharm Biomed Anal; 2014 Aug; 96():135-43. PubMed ID: 24742772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A validated stability-indicating RP-HPLC method for levofloxacin in the presence of degradation products, its process related impurities and identification of oxidative degradant.
    Lalitha Devi M; Chandrasekhar KB
    J Pharm Biomed Anal; 2009 Dec; 50(5):710-7. PubMed ID: 19632800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the forced degradation behavior of prasugrel hydrochloride by liquid chromatography with mass spectrometry and liquid chromatography with NMR detection and prediction of the toxicity of the characterized degradation products.
    Singh DK; Sahu A; Handa T; Narayanam M; Singh S
    J Sep Sci; 2015 Sep; 38(17):2995-3005. PubMed ID: 26114771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forced degradation of recombinant monoclonal antibodies: A practical guide.
    Nowak C; K Cheung J; M Dellatore S; Katiyar A; Bhat R; Sun J; Ponniah G; Neill A; Mason B; Beck A; Liu H
    MAbs; 2017; 9(8):1217-1230. PubMed ID: 28853987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LC-MS/MS structural characterization of stress degradation products including the development of a stability indicating assay of Darunavir: An anti-HIV drug.
    Rao RN; Ramachandra B; Sravan B; Khalid S
    J Pharm Biomed Anal; 2014 Feb; 89():28-33. PubMed ID: 24252722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degradation kinetics study of cabozantinib by a novel stability-indicating LC method and identification of its major degradation products by LC/TOF-MS and LC-MS/MS.
    Wu C; Xu X; Feng C; Shi Y; Liu W; Zhu X; Zhang J
    J Pharm Biomed Anal; 2014 Sep; 98():356-63. PubMed ID: 24992215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of new impurities of enalapril maleate on oxidation in the presence of magnesium monoperoxyphthalate.
    Toporisic R; Mlakar A; Hvala J; Prislan I; Zupancic-Kralj L
    J Pharm Biomed Anal; 2010 Jun; 52(2):294-9. PubMed ID: 20122808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A stability-indicating HPLC assay with diode array detection for the determination of a benzylpenicillin prodrug in aqueous solutions.
    Jain R; Wu Z; Tucker IG
    J Pharm Biomed Anal; 2009 Dec; 50(5):841-6. PubMed ID: 19640667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A validated stability-indicating LC method for acetazolamide in the presence of degradation products and its process-related impurities.
    Srinivasu P; Subbarao DV; Vegesna RV; Sudhakar Babu K
    J Pharm Biomed Anal; 2010 May; 52(1):142-8. PubMed ID: 20053517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Forced degradation of fingolimod: effect of co-solvent and characterization of degradation products by UHPLC-Q-TOF-MS/MS and 1H NMR.
    Patel PN; Kalariya PD; Gananadhamu S; Srinivas R
    J Pharm Biomed Anal; 2015 Nov; 115():388-94. PubMed ID: 26279369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of degradation products of ivabradine by LC-HR-MS/MS: a typical case of exhibition of different degradation behaviour in HCl and H2SO4 acid hydrolysis.
    Patel PN; Borkar RM; Kalariya PD; Gangwal RP; Sangamwar AT; Samanthula G; Ragampeta S
    J Mass Spectrom; 2015 Feb; 50(2):344-53. PubMed ID: 25800016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Degradation Chemistry of Farglitazar and Elucidation of the Oxidative Degradation Mechanisms.
    Reynolds DW; Campbell JM; Johnson BS; Joshi BK; Facchine KL; Long S; O'Connell TM; Paulus IV; Sides SL; Kraft ES; Wolters AM
    J Pharm Sci; 2017 Apr; 106(4):982-993. PubMed ID: 27988163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.